(I'm looking for a place in this one... Arotech is significantly undervalued despite being a small and growing firm with promising future bullish catalysts. ARTX offers solid fundamentals, highlighted by the Piotroski F-Score, that are rarely seen with companies comparable to it. Taking all into consideration we believe that ARTX is currently undervalued by 50% and are setting a short-term price target of $7.85.